Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysis
Abstract Background Tumor characteristics can be prognostically relevant in patients with high‐grade serous ovarian carcinoma (HGSOC). This study aimed to determine whether different subtypes of HGSOC, especially the mesenchymal subtype, are associated with overall survival (OS) or progression‐free...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4752 |
| _version_ | 1811340141333053440 |
|---|---|
| author | Juan Chen Xiaoyan Shi Lan Xiao Zelian Li Zhimin Li Lei Sun |
| author_facet | Juan Chen Xiaoyan Shi Lan Xiao Zelian Li Zhimin Li Lei Sun |
| author_sort | Juan Chen |
| collection | DOAJ |
| description | Abstract Background Tumor characteristics can be prognostically relevant in patients with high‐grade serous ovarian carcinoma (HGSOC). This study aimed to determine whether different subtypes of HGSOC, especially the mesenchymal subtype, are associated with overall survival (OS) or progression‐free survival (PFS) in patients with HGSOC. Methods PubMed, Embase, and the Cochrane Library were searched for studies published up to September 2020. The eligibility criteria were (1) population: patients with HGSOG with molecular subtyping of their tumor, (2) exposure: mesenchymal subtype, (3) non‐exposure: differentiated, immunoreactive, proliferative, and other non‐mesenchymal subtypes, (4) outcome: survival, with hazard ratios (HRs), and (5) English language. Results The mesenchymal subtype showed no statistically significant difference in OS compared with the immunoreactive subtype (HR = 1.47, 95% CI: 0.78–2.78, p = 0.238; I2 = 81.2%, pheterogeneity = 0.005) or all non‐mesenchymal subtypes (HR = 1.65, 95% CI: 0.97–2.80, p = 0.063; I2 = 79.4%, pheterogeneity = 0.008). The mesenchymal subtype showed no statistically significant difference in PFS compared with the immunoreactive subtype (HR = 1.19, 95% CI: 0.71–2.00, p = 0.514; I2 = 71.6%, pheterogeneity = 0.030) but a significant differences was observed when using all non‐mesenchymal subtypes as reference (HR = 1.51, 95% CI: 1.00–2.28, p = 0.049). The results were robust according to the sensitivity analyses. Conclusions There are no statistically significant differences in OS between the mesenchymal subtype of HGSOC and other subtypes of HGSOC. Because of statistical power, this meta‐analysis cannot conclude about non‐inferiority, and the relationship between the molecular subtypes and HGSOC prognosis remains controversial. Based on one study, the mesenchymal subtype could have a poorer PFS than the non‐mesenchymal subtypes of HGSOC, but this conclusion requires further evidence. |
| first_indexed | 2024-04-13T18:37:44Z |
| format | Article |
| id | doaj.art-24d0d2ea0e9d4bcfb4e0599cb9985ea9 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-13T18:37:44Z |
| publishDate | 2022-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-24d0d2ea0e9d4bcfb4e0599cb9985ea92022-12-22T02:34:50ZengWileyCancer Medicine2045-76342022-10-0111203761377010.1002/cam4.4752Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysisJuan Chen0Xiaoyan Shi1Lan Xiao2Zelian Li3Zhimin Li4Lei Sun5Department of Obstetrics & Gynecology First Affiliated Hospital of Anhui Medical University Hefei ChinaCentral Laboratory, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology Wuhan ChinaDepartment of Obstetrics & Gynecology First Affiliated Hospital of Anhui Medical University Hefei ChinaDepartment of Obstetrics & Gynecology First Affiliated Hospital of Anhui Medical University Hefei ChinaDepartment of Gynecology Guangdong Women and Children Hospital Guangzhou ChinaDepartment of Obstetrics & Gynecology First Affiliated Hospital of Anhui Medical University Hefei ChinaAbstract Background Tumor characteristics can be prognostically relevant in patients with high‐grade serous ovarian carcinoma (HGSOC). This study aimed to determine whether different subtypes of HGSOC, especially the mesenchymal subtype, are associated with overall survival (OS) or progression‐free survival (PFS) in patients with HGSOC. Methods PubMed, Embase, and the Cochrane Library were searched for studies published up to September 2020. The eligibility criteria were (1) population: patients with HGSOG with molecular subtyping of their tumor, (2) exposure: mesenchymal subtype, (3) non‐exposure: differentiated, immunoreactive, proliferative, and other non‐mesenchymal subtypes, (4) outcome: survival, with hazard ratios (HRs), and (5) English language. Results The mesenchymal subtype showed no statistically significant difference in OS compared with the immunoreactive subtype (HR = 1.47, 95% CI: 0.78–2.78, p = 0.238; I2 = 81.2%, pheterogeneity = 0.005) or all non‐mesenchymal subtypes (HR = 1.65, 95% CI: 0.97–2.80, p = 0.063; I2 = 79.4%, pheterogeneity = 0.008). The mesenchymal subtype showed no statistically significant difference in PFS compared with the immunoreactive subtype (HR = 1.19, 95% CI: 0.71–2.00, p = 0.514; I2 = 71.6%, pheterogeneity = 0.030) but a significant differences was observed when using all non‐mesenchymal subtypes as reference (HR = 1.51, 95% CI: 1.00–2.28, p = 0.049). The results were robust according to the sensitivity analyses. Conclusions There are no statistically significant differences in OS between the mesenchymal subtype of HGSOC and other subtypes of HGSOC. Because of statistical power, this meta‐analysis cannot conclude about non‐inferiority, and the relationship between the molecular subtypes and HGSOC prognosis remains controversial. Based on one study, the mesenchymal subtype could have a poorer PFS than the non‐mesenchymal subtypes of HGSOC, but this conclusion requires further evidence.https://doi.org/10.1002/cam4.4752gene signaturemesenchymal subtypemeta‐analysisovarian cancerprognosissurvival |
| spellingShingle | Juan Chen Xiaoyan Shi Lan Xiao Zelian Li Zhimin Li Lei Sun Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysis Cancer Medicine gene signature mesenchymal subtype meta‐analysis ovarian cancer prognosis survival |
| title | Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysis |
| title_full | Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysis |
| title_fullStr | Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysis |
| title_full_unstemmed | Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysis |
| title_short | Better or worse? The prognostic role of the mesenchymal subtype in patients with high‐grade serous ovarian carcinoma: A systematic review and meta‐analysis |
| title_sort | better or worse the prognostic role of the mesenchymal subtype in patients with high grade serous ovarian carcinoma a systematic review and meta analysis |
| topic | gene signature mesenchymal subtype meta‐analysis ovarian cancer prognosis survival |
| url | https://doi.org/10.1002/cam4.4752 |
| work_keys_str_mv | AT juanchen betterorworsetheprognosticroleofthemesenchymalsubtypeinpatientswithhighgradeserousovariancarcinomaasystematicreviewandmetaanalysis AT xiaoyanshi betterorworsetheprognosticroleofthemesenchymalsubtypeinpatientswithhighgradeserousovariancarcinomaasystematicreviewandmetaanalysis AT lanxiao betterorworsetheprognosticroleofthemesenchymalsubtypeinpatientswithhighgradeserousovariancarcinomaasystematicreviewandmetaanalysis AT zelianli betterorworsetheprognosticroleofthemesenchymalsubtypeinpatientswithhighgradeserousovariancarcinomaasystematicreviewandmetaanalysis AT zhiminli betterorworsetheprognosticroleofthemesenchymalsubtypeinpatientswithhighgradeserousovariancarcinomaasystematicreviewandmetaanalysis AT leisun betterorworsetheprognosticroleofthemesenchymalsubtypeinpatientswithhighgradeserousovariancarcinomaasystematicreviewandmetaanalysis |